Taken together, these findings suggest that silencing of LRP5 could inhibit CSC‐like phenotype by blocking the canonical Wnt/β‐catenin and IL‐6/STAT3 pathways, and targeting the overexpressed LRP5 might be a promising therapeutic approach for CRC. The gene discussed is LRP5; the disease is colorectal carcinoma.